{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:31:27Z","timestamp":1764174687735,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"LEO Pharma"},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007731","name":"Endo International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011284","name":"Valeant","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011284","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011284","name":"Valeant","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011284","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012317","name":"Astellas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008708","name":"Australian Wool Innovation Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013988","name":"Dermira","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013988","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001316","name":"Abbott","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015756","name":"Janssen-Cilag","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jaad.2019.07.083","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T19:56:59Z","timestamp":1564516619000},"page":"642-650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of ingenol mebutate gel in field treatment of actinic keratosis on full face, balding scalp, or approximately 250 cm2 on the chest: A phase 3 randomized controlled trial"],"prefix":"10.1016","volume":"82","author":[{"given":"C. William","family":"Hanke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorne","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Skov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Louise","family":"\u00d8sterdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda","family":"Spelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1 Suppl 1","key":"10.1016\/j.jaad.2019.07.083_bib1","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jaad.2012.09.053","article-title":"Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation","volume":"68","author":"Berman","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"1 Suppl 1","key":"10.1016\/j.jaad.2019.07.083_bib2","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jaad.2012.10.001","article-title":"The importance of early diagnosis and treatment of actinic keratosis","volume":"68","author":"Rigel","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.07.083_bib3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/09546634.2016.1254328","article-title":"Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology","volume":"28","author":"Dirschka","year":"2017","journal-title":"J Dermatolog Treat"},{"issue":"11","key":"10.1016\/j.jaad.2019.07.083_bib4","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/cncr.24284","article-title":"Actinic keratoses: natural history and risk of\u00a0malignant transformation in the Veterans Affairs Topical\u00a0Tretinoin Chemoprevention Trial","volume":"115","author":"Criscione","year":"2009","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2019.07.083_bib5","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1067\/mjd.2000.103339","article-title":"The risk of progression to invasive disease","volume":"42","author":"Glogau","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.07.083_bib6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.1986.tb06644.x","article-title":"Spontaneous remission of solar keratoses: the case for conservative management","volume":"115","author":"Marks","year":"1986","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.07.083_bib7","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jdv.12848","article-title":"Actinic\u00a0keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin","volume":"29","author":"Fernandez-Figueras","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2019.07.083_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2133.2007.08268.x","article-title":"Management of field change in actinic keratosis","volume":"157","author":"Vatve","year":"2007","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.07.083_bib9","first-page":"415","article-title":"Actinic keratosis as a marker of field cancerization in excision specimens of cutaneous malignancies","volume":"97","author":"Lanoue","year":"2016","journal-title":"Cutis"},{"issue":"4","key":"10.1016\/j.jaad.2019.07.083_bib10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1517\/14728214.2010.507191","article-title":"Emerging drugs for actinic keratosis","volume":"15","author":"Ulrich","year":"2010","journal-title":"Expert Opin Emerg Drugs"},{"author":"Werner","key":"10.1016\/j.jaad.2019.07.083_bib11"},{"issue":"3","key":"10.1016\/j.jaad.2019.07.083_bib12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/CAD.0b013e3280149ec5","article-title":"Proceedings of the First International Conference on PEP005","volume":"18","author":"Ogbourne","year":"2007","journal-title":"Anticancer Drugs"},{"issue":"10","key":"10.1016\/j.jaad.2019.07.083_bib13","first-page":"1181","article-title":"Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells","volume":"11","author":"Stahlhut","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2019.07.083_bib14","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1158\/0008-5472.CAN-03-2837","article-title":"Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death","volume":"64","author":"Ogbourne","year":"2004","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.jaad.2019.07.083_bib15","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1158\/0008-5472.CAN-03-3403","article-title":"Characterization of the interaction of ingenol\u00a03-angelate with protein kinase C","volume":"64","author":"Kedei","year":"2004","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.jaad.2019.07.083_bib16","doi-asserted-by":"crossref","first-page":"e0153975","DOI":"10.1371\/journal.pone.0153975","article-title":"IL-1 contributes to the anti-cancer efficacy of ingenol mebutate","volume":"11","author":"Le","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jaad.2019.07.083_bib17","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jid.2015.12.020","article-title":"Establishment of two mouse models for CEDNIK syndrome reveals the pivotal role of SNAP29 in epidermal differentiation","volume":"136","author":"Schiller","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.07.083_bib18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2010.12.038","article-title":"Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response","volume":"66","author":"Rosen","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2019.07.083_bib21","first-page":"19","article-title":"Tolerability and pharmacokinetics of ingenol mebutate 0.05% gel applied to treatment areas up to 100 cm2 on the forearm(s) of patients with actinic keratosis","volume":"7","author":"Anderson","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.07.083_bib22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/09546634.2017.1329506","article-title":"Pharmacokinetics of ingenol mebutate gel under maximum use conditions in large treatment areas","volume":"29","author":"Bucko","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2019.07.083_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"10.1016\/j.jaad.2019.07.083_bib24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/120347540100500202","article-title":"Measurement properties of Skindex-16: a brief quality-of-life measure for\u00a0patients with skin diseases","volume":"5","author":"Chren","year":"2001","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"10.1016\/j.jaad.2019.07.083_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s13555-014-0059-9","article-title":"A new, objective, quantitative scale for measuring local skin responses following topical actinic keratosis therapy with ingenol mebutate","volume":"4","author":"Rosen","year":"2014","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"10.1016\/j.jaad.2019.07.083_bib26","first-page":"438","article-title":"Safety and efficacy of escalating doses of ingenol mebutate for field treatment of actinic keratosis on the full face, full balding scalp, or chest","volume":"16","author":"Hanke","year":"2017","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.07.083_bib27","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/DSS.0000000000000989","article-title":"Variables in cryosurgery technique associated with clearance of actinic keratosis","volume":"43","author":"Berman","year":"2017","journal-title":"Dermatol Surg"},{"issue":"9","key":"10.1016\/j.jaad.2019.07.083_bib28","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1365-4632.2012.05776.x","article-title":"Understanding efficacy end-points in studies of field-directed therapy for actinic keratosis","volume":"52","author":"Wolf","year":"2013","journal-title":"Int J\u00a0Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.07.083_bib29","first-page":"166","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies","volume":"13","author":"Swanson","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.07.083_bib30","doi-asserted-by":"crossref","first-page":"e96829","DOI":"10.1371\/journal.pone.0096829","article-title":"A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe","volume":"9","author":"Vegter","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jaad.2019.07.083_bib31","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2009.07.004","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles","volume":"62","author":"Swanson","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2019.07.083_bib32","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1111\/jdv.13063","article-title":"Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% 5-fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial","volume":"29","author":"Samorano","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2019.07.083_bib33","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/bjd.17131","article-title":"Adverse effects of topical photodynamic therapy: a consensus review and approach to management","volume":"180","author":"Ibbotson","year":"2018","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.07.083_bib34","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2013.2766","article-title":"Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses","volume":"149","author":"Lebwohl","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2019.07.083_bib35","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1056\/NEJMoa1811850","article-title":"Randomized trial of four treatment approaches for actinic keratosis","volume":"380","author":"Jansen","year":"2019","journal-title":"New Engl J\u00a0Med"},{"issue":"11","key":"10.1016\/j.jaad.2019.07.083_bib36","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","article-title":"Ingenol mebutate gel for actinic keratosis","volume":"366","author":"Lebwohl","year":"2012","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2019.07.083_bib37","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jaad.2009.01.008","article-title":"Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis","volume":"60","author":"Anderson","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.07.083_bib38","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaad.2015.11.034","article-title":"Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): a randomized clinical trial","volume":"74","author":"Erlendsson","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2019.07.083_bib39","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1097\/DSS.0000000000000503","article-title":"Cosmetic effects of ingenol mebutate gel in the treatment of field-cancerized photodamaged skin","volume":"41","author":"Braun","year":"2015","journal-title":"Dermatol Surg"},{"issue":"8","key":"10.1016\/j.jaad.2019.07.083_bib40","first-page":"31","article-title":"A prospective pilot clinical trial to evaluate the efficacy and safety of topical therapy with ingenol mebutate gel 0.015% for actinic keratosis on an expanded area of the chest","volume":"10","author":"Wu","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.07.083_bib41","first-page":"13","article-title":"Ingenol mebutate 0.06% gel for field treatment of actinic keratosis on 250 cm2 of skin on trunk and extremities: a randomized dose-finding trial","volume":"1","author":"Siegel","year":"2017","journal-title":"SKIN"},{"issue":"4","key":"10.1016\/j.jaad.2019.07.083_bib42","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bjd.16368","article-title":"A multicentre, open, investigator-initiated phase IV clinical trial to evaluate the efficacy and safety of ingenol mebutate gel, 0.015% on the face and scalp, and 0.05% on the trunk and extremities, in Korean patients with actinic keratosis (PERFECT)","volume":"179","author":"Kim","year":"2018","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.07.083_bib43","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjd.12629","article-title":"Improvement in precision of counting actinic keratoses","volume":"170","author":"Lee","year":"2014","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2019.07.083_bib44","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/jdv.14267","article-title":"A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index","volume":"31","author":"Dirschka","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.jaad.2019.07.083_bib45","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2340\/00015555-2710","article-title":"A novel actinic keratosis field assessment scale for grading actinic keratosis disease severity","volume":"97","author":"Dreno","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2019.07.083_bib46","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/jdv.14652","article-title":"Defining the actinic keratosis field: a literature review and discussion","volume":"32","author":"Figueras Nart","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219324764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219324764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:53:09Z","timestamp":1759272789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219324764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0190962219324764"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.07.083","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of ingenol mebutate gel in field treatment of actinic keratosis on full face, balding scalp, or approximately 250 cm2 on the chest: A phase 3 randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.07.083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}